Protagonist Therapeutics

Yahoo Finance • 8 months ago

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story

Yahoo Finance • 10 months ago

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

Overview of Steven Cohen (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has detected 5 Warning Signs with PTGX. Steven Cohen (Trades, Portfolio)'s firm, Point72 Asset Management, has recently made a notable adjustment... Full story

Yahoo Finance • 11 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's InvestigationalInjectable Hepcidin Mimetic Currentl... Full story

Yahoo Finance • 12 months ago

A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Key Insights Protagonist Therapeutics' estimated fair value is US$27.16 based on 2 Stage Free Cash Flow to Equity With US$22.93 share price, Protagonist Therapeutics appears to be trading close to its estimated fair value Analyst price ta... Full story

Yahoo Finance • 2 years ago

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235). JNJ-2113 is a macrocyclic pe... Full story

Yahoo Finance • 2 years ago

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomize... Full story

Yahoo Finance • 2 years ago

Why Protagonist Therapeutics Shares Are Trading Higher Today

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson (NYSE: JNJ), in the FRONTIER 1 Phase 2b trial of oral Interleukin-23 receptor (IL-23R) antag... Full story

Yahoo Finance • 2 years ago

Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting

NEWARK, Calif., Nov. 3, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that three abstracts related to the Company's rusfertide program have been accepted as poster presentati... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ: PTGX).   Such investors are advised to contact Robert S... Full story

Yahoo Finance • 3 years ago

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Protagonist Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – PTGX

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resultin... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- April 19, 2021 (GLOBENEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ: PTGX). Such investors ar... Full story